(Updates with attribution to Eli Lilly throughout.)
Eli Lilly (LLY) said Thursday that India's Central Drugs Standard Control Organization has granted marketing authorization for its Mounjaro obesity and type 2 diabetes drug in the KwikPen presentation.
All six dosage options for Mounjaro will be available in India soon, the drugmaker said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。